yingweiwo

Resiquimod (R848)

Alias: R-848; S-28463; VML600;R848; S 28463; VML 600;R 848;S28463; VML-600.
Cat No.:V1867 Purity: ≥98%
Resiquimod(formerly known as R-848; S-28463; VML-600;R848, S27609)is a potent imidazoquinolinamine-based immune response modifier that acts as an agonist of the TLR 7/8 receptors (Toll-like receptor 7/8) withantiviral and antitumour activity.
Resiquimod (R848)
Resiquimod (R848) Chemical Structure CAS No.: 144875-48-9
Product category: TLR
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
10mg
25mg
50mg
100mg
250mg
Other Sizes

Other Forms of Resiquimod (R848):

  • Resiquimod-d5
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
InvivoChem's Resiquimod (R848) has been cited by 2 publications
Purity & Quality Control Documentation

Purity: ≥98%

Product Description

Resiquimod (formerly known as R-848; S-28463; VML-600; R848, S27609) is a potent imidazoquinolinamine-based immune response modifier that acts as an agonist of the TLR 7/8 receptors (Toll-like receptor 7/8) with antiviral and antitumour activity. It can induce the levels of cytokines such as TNF-α, IL-6 and IFN-α. Resiquimod is the analogue of imiquimod (also called R-837,S-26308) with potential immunostimulatory activity. Resiquimod has been reported to dose-dependently induce cytokines including IFN, TNF, IL-1β and IL-6 in human peripheral blood mononuclear (PBMCs). In addition, Resiquimod has been revealed to stimulate intracellular IL-1β increased approximately 15%. The results have also been noted that both monocytes and B cells produced IFN in response to Resiquimod. On April 28, 2016, orphan designation (EU/3/16/1653) was granted by the European Commission to resiquimod for the treatment of cutaneous T-cell lymphoma.

Biological Activity I Assay Protocols (From Reference)
Targets
Toll-like Receptor 7/8 (TLR7/8)
ln Vitro
Resiquimod (R-848) causes circulating T cells (including TH2 effectors) that are specific to haptens and allergens to produce IFN-γ and even lose their capacity to produce IL-4 [2]. In BrdU incorporation experiments, resiquimod (R848) increases the number of BrdU-positive cells and, in a dose-dependent manner, boosts PBL proliferation. The reporter of NF-κB activity, luciferase, significantly increased (3.5-fold) in cells treated with R848 [3].
ln Vivo
Rats and mice can be utilized as models for immune-mediated cardiac tissue injury and cytokine production with Resiquimod in animal modeling. In SPF chickens, the intramuscular injection of Resiquimod (R-848) at a dose of 50 μg/bird dramatically increased the production of IFN-α, IFN-β, IFN-γ, IL-1β, IL-4, iNOS, and MHC-II genes [1].
Enzyme Assay
BrdU incorporation assay[3]
For BrdU incorporation assay, R848 (1 µg/ml), CQ (10 µM), CQ plus R848 or PBS were added to PBL in a 6-well tissue culture plate as described earlier (2 × 106 cells/well). The cells were incubated at 22 °C for 48 h, and cellular proliferation was detected with BrdU Cell Proliferation Assay Kit according to the manufacturer's instructions. The assay was performed three times.
Luciferase reporter assay[3]
For luciferase assay, FG-9307 cells were transfected with the firefly NF-κB–specific luciferase reporter vector pNFκB-Met-Luc2 (Clontech, Mountain View, CA, USA) as described previously (Chi et al., 2013). pNFκB-MetLuc2 is designed to monitor the activation of the NF-κB signal transduction pathway directly from the cell culture medium. The vector contains an NF-κB enhancer element located upstream of the minimal TA promoter (PTA). Located downstream of PTA is a secreted-luciferase gene. Binding of transcription factors to the NF-κB enhancer element allows MetLuc to be expressed and secreted into the surrounding medium. pNFκB-MetLuc2 has been demonstrated to work in fish system (Lauksund et al., 2009). Transfection efficiency was monitored by co-transfection with the pSEAP2 control vector, which constitutively expresses the human secreted enhanced alkaline phosphatase (SEAP). Then the cells were treated with R848 (1 µg/ml), CQ (10 µM), CQ plus R848 or PBS and incubated at 22 °C for 24 h. The culture medium of the transfectants was then analyzed for luciferase activity and SEAP activity using Luciferase Assay Kit and the Great EscAPe™ SEAP Chemiluminescence Detection Kit, respectively. The assay was performed three times.
Cell Assay
MTT assay to determine cellular proliferation[3]
To prepare PBL, blood was collected from the caudal veins of flounder and diluted 1:5 with L-15 medium. The diluted blood was placed on top of 61% Percoll and centrifuged at 400 × g for 30 min. The layer of PBL was recovered and washed three times with PBS. The cells were distributed in 96-well tissue culture plates (5 × 105 cells/well) in L-15 medium containing 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 µg/ml streptomycin. The cells were treated with different concentrations (0, 0.175, 0.25, 0.5, 1, 2, 4, 8, and 16 µg/ml) of R848 for 48 h. For inhibition of lysosomal acidification, cells were incubated with 10 µM CQ for 1 h before R848 treatment. After treatment, 20 µl of 5 mg/ml MTT {3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di- phenytetrazoliumromide} was added to the plate. The plate was incubated at 22 °C for 4 h, and 200 µl dimethyl sulfoxide was added to the plate to dissolve the reduced formazan. The plate was then read at 490 nm with a microplate reader. To determine the effect of Myd88 inhibition on R848-induced cell proliferation, the Myd88 inhibitor Pepinh-MYD (RQIKIWFQNRRMKWKK-RDVLPGTCVNS-NH2) and the control peptide Pepinh-Control (RQIKIWFQNRRMKWKK-SLHGRGDPMEAFII-NH2) were added to PBL at the concentration of 50 µM, and the plate was incubated at 22 °C for 6 h. After incubation, the cells were treated with R848 and subjected to MTT assay as above. To determine the effect of NF-κB inactivation on R848-induced cell proliferation, BAY-11-7082, an irreversible inhibitor of IκB-α phosphorylation, was added to the cells at the concentration of 1 µM, and the plate was incubated at 22 °C for 1 h. After incubation, the cells were treated with R848 and subjected to MTT assay as earlier. All experiments were performed three times.
Apoptoses assay[3]
PBL prepared earlier were distributed in 12-well tissue culture plates (1 × 106 cells/well) in L-15 medium containing 10% FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin. R848 (1 µg/ml), CQ (10 µM), CQ plus R848 or PBS were added to the cells, and the cells were incubated at 22 °C for 12 h or 48 h. After incubation, the cells were washed twice with cold PBS. The washed cells were treated with FITC-conjugated annexin V and propidium iodide (PI) by using annexin V-FITC and PI Cell Apoptosis Detection Kit according to the manufacturer's instructions. The cells were then subjected to flow cytometry using a FACSort Flow Cytometer equipped with FlowJo software (Tree Star Inc, Ashland OR) for data analysis. To determine the effect of Myd88 inhibition on apoptosis, Pepinh-MYD and Pepinh-Control were added to PBL at the concentration of 50 µM. After incubation at 22 °C for 6 h, the cells were treated with R848 and subjected to annexin V/PI assay as earlier. To determine the effect of NF-κB inactivation on R848-induced anti-apoptosis, BAY-11-7082 was added to the cells at the concentration of 1 µM. After incubated at 22 °C for 1 h, the cells were treated with R848 and subjected to annexin V/PI assay as earlier. All experiments were performed three times.
Quantitative real-time reverse transcription-PCR (qRT-PCR)[3]
Total RNA was extracted from PBL with the RNAprep Tissue Kit. One microgram of total RNA was used for cDNA synthesis with M-MLV reverse transcriptase. qRT-PCR was carried out in an Eppendorf Mastercycler using the SYBR ExScript qRT-PCR Kit as described previously (Zheng and Sun, 2011). Melting curve analysis of amplification products was performed at the end of each PCR to confirm that only one PCR product was amplified and detected. The expression level of the target gene was analyzed using comparative threshold cycle method with beta-actin as the internal reference (Zhang et al., 2013). The experiment was performed three times.
Animal Protocol
R848 and chloroquine (CQ) were resuspended in PBS to 200 µg/ml and 100 µM respectively. Japanese flounder (average 11.6 g) were divided randomly into four groups and administered by intramuscular (i.m.) injection with 50 µl R848, CQ, R848 plus CQ, or PBS. At 24 h post-administration, the fish were challenged by intraperitoneal (i.p.) injection with 50 µl megalocytivirus that had been suspended in PBS to 1 × 107 copies/ml. At 3 d, 5 d, and 7 d post-challenge, kidney and spleen were collected from the fish (4 fish/time point), and the viral amounts in the tissues were determined by absolute quantitative real time PCR as reported previously (Zhang et al., 2012). The experiment was performed three times[3].
Although the solitary adjuvant potential of R-848 is well established in mammals, such reports are not available in avian species hitherto. Hence, the adjuvant potential of R-848 was tested in SPF chicken in this study. Two week old chicks were divided into four groups (10 birds/group) viz., control (A), inactivated Newcastle disease virus (NDV) vaccine prepared from velogenic strain (B), commercial oil adjuvanted inactivated NDV vaccine prepared from lentogenic strain (C) and inactivated NDV vaccine prepared from velogenic strain with R-848 (D). Booster was given two weeks post primary vaccination. Humoral immune response was assessed by haemagglutination inhibition (HI) test and ELISA while the cellular immune response was quantified by lymphocyte transformation test (LTT) and flow cytometry post-vaccination. Entire experiment was repeated twice to check the reproducibility. Highest HI titre was observed in group D at post booster weeks 1 and 2 that corresponds to mean log2 HI titre of 6.4 ± 0.16 and 6.8 ± 0.13, respectively. The response was significantly higher than that of group B or C (P<0.01). LTT stimulation index (P ≤ 0.01) as well as CD4(+) and CD8(+) cells in flow cytometry (P<0.05) were significantly high and maximum in group D. Group D conferred complete protection against virulent NDV challenge, while it was only 80% in group B and C. To understand the effects of R-848, the kinetics of immune response genes in spleen were analyzed using quantitative real-time PCR after R-848 administration (50 μg/bird, i.m. route). Resiquimod significantly up-regulated the expression of IFN-α, IFN-β, IFN-γ, IL-1β, IL-4, iNOS and MHC-II genes (P<0.01). In conclusion, the study demonstrated the adjuvant potential of R-848 when co-administered with inactivated NDV vaccine in SPF chicken which is likely due to the up-regulation of immune response genes[1].
Dissolved in saline; 50 nmol; i.p. injection
Wild-type mice, TLR7-deficient mice, and MyD88-deficient mice
References
[1]. Sachan S, et al. Adjuvant potential of resiquimod with inactivated Newcastle disease vaccine and its mechanism of action in chicken. Vaccine. 2015 Aug 26;33(36):4526-32.
[2]. Brugnolo F, et al. The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ TH2 lymphocytes into IFN-gamma-producing cells. J Allergy Clin Immunol. 2003 Feb;111(2):380-8.
[3]. Zhou ZX, et al. Immune effects of R848: evidences that suggest an essential role of TLR7/8-induced, Myd88- and NF-κB-dependent signaling in the antiviral immunity of Japanese flounder (Paralichthys olivaceus). Dev Comp Immunol. 2015 Mar;49(1):113-20
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C17H22N4O2
Molecular Weight
314.38
Exact Mass
314.17428
Elemental Analysis
C, 64.95; H, 7.05; N, 17.82; O, 10.18
CAS #
144875-48-9
Related CAS #
Resiquimod-d5;2252319-44-9;Resiquimod;144875-48-9
Appearance
White to light yellow solid
LogP
2.15
tPSA
86.19
SMILES
CC(O)(C)CN1C(COCC)=NC2=C1C3=CC=CC=C3N=C2N
InChi Key
BXNMTOQRYBFHNZ-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H22N4O2/c1-4-23-9-13-20-14-15(21(13)10-17(2,3)22)11-7-5-6-8-12(11)19-16(14)18/h5-8,22H,4,9-10H2,1-3H3,(H2,18,19)
Chemical Name
1-(4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol
Synonyms
R-848; S-28463; VML600;R848; S 28463; VML 600;R 848;S28463; VML-600.
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO:63 mg/mL (200.4 mM)
Water:<1 mg/mL
Ethanol:21 mg/mL (66.8 mM)
Solubility (In Vivo)
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.95 mM) (saturation unknown) in 5% DMSO + 40% PEG300 + 5% Tween80 + 50% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 2.08 mg/mL (6.62 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

View More

Solubility in Formulation 3: ≥ 2.08 mg/mL (6.62 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.


Solubility in Formulation 4: ≥ 2.08 mg/mL (6.62 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL corn oil and mix evenly.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 3.1809 mL 15.9043 mL 31.8086 mL
5 mM 0.6362 mL 3.1809 mL 6.3617 mL
10 mM 0.3181 mL 1.5904 mL 3.1809 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Contact Us